Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 49
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

- (2011) Volume 3, Issue 4

Development and validation of RP-HPLC method for the determination of Atomoxetine Hydrochloride in Pharmaceutical Dosage Forms

Gurmeet Chhabra*, Chandraprakash Jain, Saurabh K BanerjeeSVKM’s, NMIMS, School of Pharmacy and Technology Management Shirpur, Dist. Dhule, M.S., India 425405
Corresponding Author: Gurmeet Chhabra E-mail: gurmeetchhabra@gmail.com
Received: 22 September 2011 Accepted: 23 October 2011
Citation: Gurmeet Chhabra*, Chandraprakash Jain,Saurabh K Banerjee “Development and validationof RP-HPLC method for the determination ofAtomoxetine Hydrochloride in PharmaceuticalDosage Forms”, Int. J. Drug Dev. & Res., Oct-Dec2011, 3(4): 275-279
Copyright: © 2010 IJDDR, Gurmeet Chhabraet al. This is an open access paper distributed underthe copyright agreement with Serials Publication,which permits unrestricted use, distribution, andreproduction in any medium, provided the originalwork is properly cited.
Related article at Pubmed, Scholar Google
Visit for more related articles at International Journal of Drug Development and Research

Abstract

A simple, reliable, specific, accurate and precise reverse phase high performance liquid chromatographic method was developed and validated for the determination of Atomoxetine HCl in pharmaceutical dosage form. Chromatographic separation was carried on RP-C8 column (Phenomenex, size: 250×4.60 mm, particle size 5μm) with a mobile phase composed of acetonitrile and 10 mM disodium hydrogen phosphate buffer with 0.1% TEA (pH 3.0, adjusted with OPA) (55:45, v/v) in isocratic mode at a flow rate of 1mL/min. The detection was monitored at 271nm. The retention time for Atomoxetine was found to be 3.08 min. The method was found to be linear in the range of 50-150μg/mL. The proposed method can be used for the estimation of Atomoxetine HCl in bulk and pharmaceutical dosage forms for routine quality control analysis

Key words

Atomoxetine HCl, RP-HPLC

INTRODUCTION

Atomoxetine (ATX) - (R)-N-methyl-3-phenyl-3-(otolyloxy)- propylamine hydrochloride is a medication used for the treatment of attention deficit/hyperactivity disorder (ADHD). Atomoxetine in the form of the hydrochloride salt is the only drug from its class, a highly selective non-stimulant norepinephrine reuptake inhibitor. It is approved for use in children (F 6 years), adolescents and adults all over.1-4 As in detail the mechanism of action is still unknown, the ex-vivo uptake and neurotransmitter depletion studies establish it to be related to highly specific presynaptic inhibition of norepinephrine transporter.5
Literature survey reveals few chromatographic methods have been reported for quantitative estimation of ATX in pharmaceutical formulations.6, 7 A ion pairing HPLC method was also reported for the separation of Atomoxetine and impurities.8 A stability-indicating RP HPLC method also reported for the determination of Atomoxetine hydrochloride in the presence of its degradation products generated from forced decomposition studies.9
The proposed RP-HPLC method is simple, precise, accurate, sensitive and validated method for the determination of Atomoxetine hydrochloride in bulk and its pharmaceutical dosage forms (tablets/capsules).

MATERIALS AND METHODS

Atomoxetine HCl was obtained as a gift samples from Ajanta Pharma Ltd. Mumbai, India. HPLC grade acetonitrile and methanol were purchased from Merck chemicals, Mumbai. AR grade disodium hydrogen phosphate anhydrous, ortho-phosphoric acid was purchased from Qualigen Fine Chemicals, Mumbai and triethlyamine from Spectrochem Pvt. Ltd. Mumbai. Formulation used in the study AXEPTA-25 tablets was purchased from the local market.
A HPLC (Perkin Elmer, USA) consisting of Binary LC Pump 200 (Perkin Elmer, Model: series 200), vacuum degasser, UV?VIS detector (Perkin Elmer, Model: series 200). A sample injector system (Rheodyne) with a 20μl sample loop and Total Chrome Navigator software (version V 6.3.1). Vacuum filtration assembly (Orchid Scientifics, Model: JVP01); Ultrasonicator (Oscar, Model: Microclean 103).

Chromatographic Conditions

HPLC analysis was carried out on C8 (Phenomenex, size: 250×4.60 mm, particle size 5μm) reversed phase column. The mobile phase consisted of a mixture of Acetonitrile and 10 mM disodium hydrogen phosphate buffer with 0.1% TEA v/v at pH 3.0 (pH 3.0, adjusted with OPA) (55:45, v/v). The flow rate of mobile phase was 1 ml/min. The detection was carried out by at 271 nm. All analysis was carried out at a temperature of 25°C under isocratic conditions.

Standard solution preparation

An accurately weighed quantity of Atomoxetine HCl drug 10 mg was transferred into 10 ml volumetric flask and was dissolved in acetonitrile solvent, then the solution was sonicated for about a minute and the volume was made up to the mark with acetonitrile to give a stock solution. From the stock solution 1mL was taken and further diluted to 10mL with acetonitrile to get final standard solution of 100μg/ml.

Sample solution preparation

For the determination of drug content in formulation, 20 tablets were each weighed and pulverised to obtain a fine powder in morter and pestle. An amount equivalent to 25 mg of Atomoxetine HCl was transferred to a 25mL volumetric flask; about 20mL of acetonitrile was added and sonicated for 5 min. Then the volume was made up to mark with acetonitrile and filtered it through whatman filter. From the filtrate 1mL was taken and further diluted to 10mL with acetonitrile to get final sample solution of 100μg/ml.

RESULTS AND DISCUSSION

Method Optimization

To optimize the operating conditions for isocratic reverse phase analysis on C8 column for detection of Atomoxetine, a number of parameters such as the mobile phase composition, pH and sample preparation solvent/diluent were varied. Methanol: buffer and acetonitrile: buffer in various ratios (65:35, 60:40, 55:45 v/v) were taken, trials showed peak distortion or tailing of peak. pH change had little to less effect as the drug is basic (pKa 10.13) in nature. Modification thus were made in the solvent used for sample preparation from buffer, buffer: acetonitrile to acetonitrile showed remarkable changes. Henceforth, in the present method sample preparation with acetonitrile alone and mobile phase of acetonitrile and 10mM disodium hydrogen phosphate buffer with 0.1% TEA v/v at pH 3.0 (pH 3.0, adjusted with OPA) (55:45, v/v) and at a flow rate of 1.0 mL/min showed good peak shape with proper elution at retention time of 3.08 min. The chromatographic parameters like peak symmetry, tailing factor and retention time were within limits and method was chosen as optimal conditions. The appropriate wavelength in UV region (271nm) was selected for the measurement of active ingredients in the proposed method.

Method Validation

System suitability parameters

System suitability parameters for repeated six injections include tailing factor, plate number (N) and percentage relative standard deviation (%RSD) for peak area were within the acceptable limits.

Linearity

From the working standard stock solution (1000 μg/mL), various concentration levels of 50, 70, 100, 120 and 150 μg/mL were prepared and injected on the optimized chromatographic conditions. Linearity curve was constructed by plotting the peak area vs the drug concentration with regression equation, y = 8897.4x + 65293, where ‘x’ is the concentration (μg/mL) and linear regression r2 = 0.9991.

Repeatability (method precision)

Six test samples (100μg/mL) were prepared under the same condition from same lot of formulation. Each sample was injected and analyzed on same day. The percentage relative standard deviation (% RSD) was calculated for the resultant peak area.

Intermediate precision

The analysis was carried on assay conc. (100μg/mL) prepared on different day by different analyst. The assay procedure was repeated six times and the chromatogram was recorded. The percentage relative standard deviation (% RSD) was calculated.

Accuracy

Accuracy was performed at 3 levels spiking of 80, 100 and 120% of standard concentration. The recovery procedure was repeated 3 times and % RSD was calculated. The values of % RSD of assay indicate the method is accurate.

CONCLUSION

The results obtained by HPLC method for determination of Atomoxetine HCl in selected pharmaceutical formulation was simple, reliable, specific, accurate and precise. Hence, it can be employed for routine quality control analysis.
 

Tables at a glance

Table icon Table icon
Table 1 Table 2
 

Figures at a glance

Figure 1 Figure 2 Figure 3
Figure 1 Figure 2 Figure 3
 
5695

References

  1. Atomoxetine - Wikipedia, the free encyclopedia. [cited, February 13, 2011] Available from: https://en.wikipedia.org/wiki/Atomoxetine
  2. USP Pending Monograph Draft 1—For Public Comment. [cited, March 16, 2011] Available from: https://www.usp.org/pdf/EN/pendingStandar ds/2010-04-m5353.pdf
  3. Atomoxetine Hydrochloride Monograph. Drugs.com. [cited, Februrary 23, 2011] Available from: https://www.drugs.com/monograph/Atomoxet ine-hydrochloride.html
  4. DrugLead. [cited, Februrary 25, 2011] Available from: https://www.druglead.com/cds/Atomoxetine
  5. Alisa KC, Joli DF, John SM Atomoxetine, a Novel Treatment for Attention-Deficit- Hyperactivity Disorder. Pharmacotherapy 2004; 24 (8).
  6. Sudhir SK, Vishal BC, Vinayak TV, Swarup SP RP-LC determination of AtomoxetineHCl from its pharmaceutical dosage form. Chromatographia 2008; 67 (1-2):143-146.
  7. Jagadeesh BV, Raju SS, Jayatritha VR, Seshagiri JR Reverse Phase HPLC analysis of Atomoxetine in pharmaceutical dosage forms. Asian Journal of Chemistry. 2009; 21 (2):829- 833.
  8. Peter FG, Bernard AO A quality by design approach to impurity method development for Atomoxetine hydrochloride (LY139603). Journal of Pharmaceutical and Biomedical Analysis.2008; 46:431–441.
  9. Sejal KP, Natvarlal JP Development and validation of a stability-indicating RP-HPLC method for determination of Atomoxetine Hydrochloride in tablets. Journal of AOAC International. 2010; 93(4): 1207-1214.
  10. Snyder LR, Kirkland JJ, Glajch JL Practical HPLC Method Development. 2nd ed. John Wiley & Sons, Inc; 1997.
  11. ICH Q2B Validation of Analytical Procedures: Methodology. International Conference on Harmonization (ICH) Harmonized Tripartite, May 1997.